Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.
Source: PharmacoEconomics - Category: Health Management Source Type: research